The Agilent InfinityLab 2D-LC Solution with Active Solvent Modulation

Similar documents
Automated Switching Between 1D-LC and Comprehensive 2D-LC Analysis

High-Resolution Sampling 2D-LC for Pharmaceutical Impurity Analysis

Performance evaluation of the Agilent 1290 Infinity 2D-LC Solution for comprehensive two-dimensional liquid chromatography

The Agilent 1260 Infinity Analytical SFC System with Time-of-Flight Mass Spectrometric Detection

Accurate quantification of oleanolic acid and ursolic acid in traditional chinese medicine

Comprehensive 2D-LC Analysis of Chinese Herbal Medicine

Analysis of DNPH-derivatized Aldehydes and Ketones using the Agilent 1220 Infinity LC System with Diode Array Detector

Determination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry

Using the Agilent 1290 Infinity II Multicolumn Thermostat with Extreme Temperatures and Flow Rates

Separation of Enantiomers of Amphetamine-Related Drugs and Their Structural Isomers

Method Development in Comprehensive 2D-LC Finding the Most Orthogonal Separation Systems for RPLC RPLC Using Column and Solvent Screening

Performance characteristics of the Agilent 1290 Infinity Quaternary Pump

Agilent 1290 Infinity Quaternary LC Stepwise Transfer to Methods with MS-Compatible Mobile Phases

Analysis of Stachydrine in Leonurus japonicus Using an Agilent ZORBAX RRHD HILIC Plus Column with LC/ELSD and LC/MS/MS

Application Note. Author. Abstract. Food Testing & Agriculture. Edgar Naegele Agilent Technologies, Inc. Waldbronn, Germany

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Analytical determination of testosterone in human serum using an Agilent Ultivo Triple Quadrupole LC/MS

Analysis of Metals, Halides, and Inorganic Ions Using Hydrophilic Interaction Chromatography

The Agilent 1290 Infinity II Multi Method Solution

Analysis of E.coli Tryptic Digest and Intact Protein Using the Agilent 1290 Infinity 2D-LC Solution with Diode Array Detection and Q-TOF LC/MS

Maximizing Triple Quadrupole Mass Spectrometry Productivity with the Agilent StreamSelect LC/MS System

MassHunter METLIN Metabolite PCD/PCDL Quick Start Guide

Accurate Mass Analysis of Hydraulic Fracturing Waters: Identification of Polyethylene Glycol Surfactants by LC/Q-TOF-MS

Plasma Metanephrines and 3-Methoxytyramine by LC/MS/MS Using Agilent SimpliQ WCX SPE, 1290 Infi nity LC, and 6460 Triple Quadrupole LC/MS

Developing a fast, generic method for rapid resolution LC with quadrupole MS detection. Application Note

Determination of Enantiomeric Excess of Metolachlor from Chiral Synthesis using the Agilent 1260 Infinity Analytical SFC System

Application Note. Authors. Abstract. Food Testing & Agriculture. Stephen E. Reichenbach University of Nebraska Lincoln, NE, USA

Determination of Hormones in Drinking Water by LC/MS/MS Using an Agilent InfinityLab Poroshell HPH Column (EPA 539)

Fast and Flexible Optimization of Modifier Concentrations Using an Agilent 1290 Infinity LC System with Blend Assist

Agilent 1200 Infinity Series HDR DAD Impurity Analyzer System for the Quantification of Trace Level of Genotoxic Impurity

Rapid method development to study plasma stability of diverse pharmaceutical compounds using Rapid Resolution LC and triple quadrupole MS

Application Note. Authors. Abstract. Energy & Chemicals, Biofuels & Alternative Energy

Separation of Large and Small Peptides by Supercritical Fluid Chromatography and Detection by Mass Spectrometry

Detection of Trace Level Pharmaceuticals in Drinking Water by Online SPE Enrichment with the Agilent 1200 Infinity Series Online-SPE Solution

Application Note Pharmaceutical QA/QC. Agilent Application Solution. Authors. Abstract. Syed Salman Lateef Agilent Technologies, Inc.

Analysis of Beer by Comprehensive 2D-LC with the Agilent 1290 Infinity 2D-LC system

Application Note. Pharmaceutical QA/QC. Author. Abstract. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Accurate Mass Measurement for Intact Proteins using ESI-oa-TOF. Application Note. Donghui Yi and Christine Miller Agilent Technologies

LC walk-up system using the Agilent 1200 Series LC Method Development Solution and Agilent Easy Access software. Application Note

Application Note. Author. Abstract. Pharmaceutical QA/QC. Vinayak A.K Agilent Technologies Bangalore, India

Accurate Mass Analysis of Hydraulic Fracturing Waters

Ultrafast and sensitive analysis of sweeteners, preservatives and flavorants in nonalcoholic beverages using the Agilent 1290 Infinity LC system

Analysis of E.coli Tryptic Digest and Intact Protein Using the Agilent 1290 Infinity 2D-LC Solution with Diode Array Detection and Q-TOF LC/MS

LC/MS/MS qua ntitation of β-estradiol 17-acetate using an Agilent 6460 Triple Quadrupole LC/MS working in ESI negative ion mode

Exceptional Selectivity of Agilent ZORBAX Eclipse Plus Phenyl-Hexyl Columns to Separate Estrogens

Pharmaceutical Impurity Identification and Profiling Using Agilent Q-TOF LC/MS Combined with Advanced MassHunter Data Processing Software

Use of the SFC-MS Splitter Kit G

Macrolides in Honey Using Agilent Bond Elut Plexa SPE, Poroshell 120, and LC/MS/MS

LC Technical Information

Rapid Screening and Confirmation of Melamine Residues in Milk and Its Products by Liquid Chromatography Tandem Mass Spectrometry

Quantification of growth promoters olaquindox and carbadox in animal feedstuff with the Agilent 1260 Infinity Binary LC system with UV detection

Taking Full Advantage of UHPLC with Agilent 6460A Triple Quadrupole MS. Outline

Analysis of Trace (mg/kg) Thiophene in Benzene Using Two-Dimensional Gas Chromatography and Flame Ionization Detection Application

Routine MS Detection for USP Chromatographic Methods

Application Note. Author. Abstract. Xinlei Yang Agilent Technologies Co. Ltd Shanghai, China

Achieve confident synthesis control with the Thermo Scientific ISQ EC single quadrupole mass spectrometer

Accelerating the Metabolite Identification Process Using High Resolution Q-TOF Data and Mass-MetaSite Software

Agilent LC & LC-MS Cannabis Testing

Agilent ESI and APCI sources: for polar to non-polar compounds

Figure 1. Structures for Vitamin B2 and Vitamin B1.

Analysis of Low-Calorie Sweeteners by Liquid Chromatography-Tandem Mass Spectrometry

Application Note. Edgar Naegele. Abstract

Application Note. Abstract. Authors. Environmental

Impact of Instrument Dispersion on Performance of HPLC Capillary Columns

UPLC Intact MASS Analysis Application Kit

MS n Analysis With Fast Polarity Switching in the Agilent 1100 Series LC/MSD Trap SL. Application Note. Christine Miller Agilent Technologies

Measuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug Conjugates (ADCs) with UHPLC/Q-TOF

How proteins separate on reverse-phase HPLC

Sensitive HILIC UHPLC-UV determination of steviol glycoside natural sweeteners

LC/MS/MS of Fungicides and Metabolites in Apple Juice with Agilent Bond Elut Plexa and Poroshell 120

Fractionation of Acidic, Basic, and Neutral Drugs from Plasma with an SPE Mixed Mode Strong Cation Exchange Polymeric Resin (Agilent SampliQ SCX)

The new Agilent 1290 Infinity Quaternary LC

Utilizing ELSD and MS as Secondary Detectors for Prep HPLC and Flash Chromatography. Tips and Techniques to Optimize ELSD and MS based Purification

Agilent G3212 GC-APCI Source

Quantitative Analysis of Water-Soluble B-Vitamins in Cereal Using Rapid Resolution LC/MS/MS. Application. Authors. Abstract.

Application Note. David A. Weil Zoltan Timar Michael Zumwalt Edgar Naegele. Abstract

Analysis of Phthalates in Body Wash using Solid-Supported Liquid-Liquid Extraction

Application Note. Author. Abstract. Food Safety. Syed Salman Lateef Agilent Technologies, Inc. Bangalore, India

LC/MS/MS of Fungicides and Metabolites in Orange Juice with Agilent Bond Elut Plexa and Poroshell 120

materials analysis Solutions for Your Analytical Business Markets and Applications Programs

Figure 1. Structures for Vitamin B2 and Vitamin B1.

HPLC Preparative Scaleup of Calcium Channel Blocker Pharmaceuticals Application

Application Note. Edgar Naegele. Abstract

It s hot! ZIC -chilic

Agilent 6400 Series Triple Quadrupole Users Workshop. MH QQQ Users workshop 2/21/2014 1

Sensitive Femtogram Determination of Aflatoxins B 1 , B 2 , G 1. and G 2. in Food Matrices using Triple Quadrupole LC/MS. Authors.

Separation of Explosives in EPA 8330: Column Choices Optimize Speed, Resolution, and Solvent Use. Application. Authors. Abstract.

The Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity

Application Note. Agilent Application Solution Analysis of acaricides in honey. Authors. Abstract. Food

Automating Method Development with an HPLC System Optimized for Scouting of Columns and Eluents

Ultrafast Analysis of Buprenorphine and Norbuprenorphine in Urine Using the Agilent RapidFire High-Throughput Mass Spectrometry System

Agilent 6460 Triple Quadrupole LC/MS System with an Agilent 1290 Infinity LC For Multi-Plant Growth Regulator Analysis in Grapes

Analysis of Positional Isomers of Lapatinib with Agilent Poroshell 120 PFP Columns

Electronic Supplementary Information

Application Note. Agilent Application Solution Analysis of PAHs in soil according to EPA 8310 method with UV and fluorescence detection.

Application. Authors. Abstract. Introduction. Hydrocarbon Processing

Determination of urea in ultrapure water by IC-MS/MS

LC-MS/MS Method for the Determination of Diclofenac in Human Plasma

Cerno Bioscience MassWorks: Acquiring Calibration Data on Agilent GC/MSDs

Analysis of USP Method <467> Residual Solvents on the Agilent 8890 GC System

Transcription:

Technical Overview The Agilent InfinityLab D-LC Solution with Active Solvent Modulation Achieving Improved Resolution and Sensitivity for Challenging Combinations of Separation Conditions Author Sonja Krieger Agilent Technologies, Inc. Abstract A major challenge during method development in two-dimensional liquid chromatography (D-LC) can be the incompatibility between the first ( D) and second dimension ( D) solvent systems. For challenging combinations of separation systems, volume overload effects such as breakthrough or broad and distorted peaks in the D can be observed. Active solvent modulation (ASM) provides a valve-based approach to address this problem, leading to improved resolution and sensitivity in the D. This Technical Overview explains the principle of ASM, and demonstrates its effect in the combination of two reversed-phase (RP) LC separations and a combination of hydrophilic interaction liquid chromatography (HILIC) and RPLC.

Introduction In situations where the sample to be analyzed is complex, or contains compounds of interest that are difficult to separate, the separation that can be achieved using one-dimensional liquid chromatography (D-LC) might not be sufficient. Two-dimensional liquid chromatography (D-LC) is then the method of choice. The Agilent InfinityLab D-LC Solution enables comprehensive (LCxLC), multiple heart-cutting (MHC), and high-resolution sampling (HiRes) D-LC to be performed. Therefore, enabling either improved separation for the entire sample (LCxLC) or separation of target compounds (MHC and HiRes D-LC), that could not be separated using D-LC. One challenge in D-LC method development can be the incompatibility between the first ( D) and second dimension ( D) solvent systems. In loop based D-LC, the analyte is transferred from the D to the D in the D effluent. When the volume of D effluent that is transferred to the D becomes significant relative to the D column dead volume, the D effluent essentially becomes the D mobile phase for a certain amount of time. For combinations of separation systems where the analytes show low retention on the D column in the D effluent, this can lead to volume overload effects, such as breakthrough or broad and distorted peaks in the D,. Active solvent modulation (ASM) addresses this problem by diluting the D effluent with D mobile phase ahead of the D column, enabling focusing of the analytes at the D column head. This Technical Overview explains the principle of active solvent modulation, and demonstrates its effect in the combination of two reversed-phase (RP) LC separations as well as a combination of hydrophilic interaction liquid chromatography (HILIC) and RPLC. Experimental Equipment The Agilent 90 Infinity II D-LC System comprised the following modules: Two Agilent 90 Infinity II High Speed Pumps (G70A) Agilent 90 Infinity II Multisampler (G767B) with cooler (option #00) Two Agilent 90 Infinity II Multicolumn Thermostats (G76B) Two Agilent 90 Infinity II Diode Array Detectors (G77B) with a 0 mm Max Light Cartridge Cell (G4-60008) Agilent 90 Infinity Valve Drive (G70A) with D-LC Valve, Active Solvent Modulation (G443A) Two Agilent 90 Infinity Valve Drives (G70A) with Multiple heart-cutting Valves (G44-64000) equipped with 40-µL loops Mass selective detection (MSD) was performed using an Agilent 650 Single Quadrupole LC/MS (G650BA) equipped with an Agilent Jet Stream ESI source (G958-65538). Software Agilent OpenLAB CDS ChemStation Edition Rev. C.0.07 SR3 [465] with D-LC Software version A.0.04. Columns Agilent ZORBAX Eclipse Plus PAH,. 00 mm,.8 µm (p/n 959764 98) Agilent ZORBAX Eclipse Plus C8 RRHD,. 50 mm,.8 µm (p/n 959757-906) Agilent ZORBAX HILIC Plus,. 00 mm, 3.5 µm (p/n 959793-90) Agilent AdvanceBio Peptide Mapping,. 00 mm,.7 µm (p/n 655750-90) Chemicals All solvents were LC grade. Acetonitrile and methanol were purchased from Merck (Darmstadt, Germany). Fresh ultrapure water was obtained from a Milli-Q Integral system equipped with a 0.-µm membrane point-of use cartridge (Millipak, EMD Millipore, Billerica, MA, USA). Ammonium formate and formic acid were purchased from Sigma-Aldrich (Steinheim, Germany) and VWR (Darmstadt, Germany), respectively. Samples and Methods RPLC-RPLC Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) A mixture of 6 polycyclic aromatic hydrocarbons (PAHs) (PAH mix 5 from Dr. Ehrenstorfer, Augsburg, Germany (YA095005AB)) was diluted with acetonitrile to obtain a concentration of 0 µg/ml of each compound. Table shows the instrument parameters. HILIC-RPLC Analysis of Peptides A peptide standard (Agilent 0 Peptide Standard, lyophilized 7 µg, p/n 590 0583) was dissolved in 00 µl water/acetonitrile (50/50, v/v) containing 0. % formic acid. Table shows the instrument parameters. The following peptides are contained in the peptide standard: Bradykinin frag -7 (Peptide ) Bradykinin (Peptide ) Angiotensin II (Peptide 3) Neurotensin (Peptide 4) Angiotensin I (Peptide 5) Renin substrate porcine (Peptide 6) [Ace-F-3,- H-] Angiotensinogen ( 4) (Peptide 7) Ser/Thr Protein Phosphatase (5-3) (Peptide 8) [F4] Ser/Thr Protein Phosphatase (5 3) (Peptide 9) Melittin (Peptide 0)

Table. RPLC-RPLC parameters. First dimension Column Agilent ZORBAX Eclipse Plus PAH,. 00 mm,.8 µm Solvent Gradient Flow rate Temperature 40 C Detection Injection A) Water B) Methanol 0 minutes 50 %B 5 minutes 00 %B Stop time: minutes Post time: 5 minutes Stop time and post time were set in the D pump to allow extension of the run time until completion of D analysis of all cuts. 0.00 ml/min DAD; 30 nm/4 nm, reference 390 nm/0 nm; 0 Hz To protect the flow cell from pressure pulses originating from valve switches, a pressure release kit (G436-6000) was installed between the D DAD and the D-LC valve. Injection volume: µl Sample temperature: 8 C Needle wash: 3 seconds in water/acetonitrile (70/30) Second dimension Column Agilent ZORBAX Eclipse Plus C8,. 50 mm,.8 µm Solvent Temperature 40 C Detection D-LC Mode Flow rate Sampling table ASM D Gradient A) Water B) Acetonitrile DAD; 30 nm/4 nm, reference 390 nm/0 nm; 80 Hz Heart-cutting.000 ml/min D-LC Time based heart-cutting with a sampling time of 0.0 minutes was set up using the D chromatogram of the PAH mixture as reference chromatogram. ASM disabled ASM and D gradient Method without the use of ASM 0.00 minutes 50 %B.00 minutes 00 %B D gradient stop time:.0 minutes D cycle time:.70 minutes ASM D Gradient ASM D Gradient ASM and D gradient Method with the use of ASM using an ASM factor of.5 ASM capillary: 5500-303 (0. 680 mm) ASM enabled (ASM factor:.5) Flush sample loop 3.0 times (0.8 minutes) 0.00 minutes 5 %B 0.8 minutes 5 %B 0.9 minutes 50 %B.9 minutes 00 %B D gradient stop time:.39 minutes D cycle time:.89 minutes ASM and D gradient Method with the use of ASM using an ASM factor of.0 ASM capillary: 5500-30 (0. 340 mm) ASM enabled (ASM factor:.0) Flush sample loop 3.0 times (0.4 minutes) 0.00 minutes 5 %B 0.4 minutes 5 %B 0.5 minutes 50 %B.5 minutes 00 %B D gradient stop time:.45 minutes D cycle time:.95 minutes 3

Table. HILIC-RPLC parameters. First dimension Column Agilent ZORBAX HILIC Plus,. 00 mm, 3.5 µm Solvent Gradient Flow rate Temperature 40 C Detection Injection A) 50 mm ammonium formate in water adjusted to ph 4.0 B) Acetonitrile 0 minutes 85 %B 0 minutes 60 %B minutes 60 %B minutes 85 %B Stop time: minutes Post time: 5 minutes Stop time and post time were set in the D pump to allow extension of the run time until completion of D analysis of all cuts. 0.500 ml/min DAD; 0 nm/4 nm, reference 360 nm/00 nm; 0 Hz To protect the flow cell from pressure pulses originating from valve switches, a pressure release kit (G436-6000) was installed between the D DAD and the D-LC valve. Injection volume: 5 µl Sample temperature: 8 C Needle wash: 3 seconds in water/acetonitrile (0/90) Second dimension Column AdvanceBio Peptide Mapping,. 00 mm,.7 µm Solvent Temperature 40 C Detection DAD MSD Signals Spray chamber A) Water + 0. % formic acid B) Acetonitrile + 0. % formic acid DAD and mass selective detection (MSD) 0 nm/4 nm, reference 360 nm/00 nm; 40 Hz Mass selective detection (MSD) Polarity: Positive Mode: Scan Mass range: 00,350 m/z Fragmentor: 00 V Gain:.00 Threshold: 50 Step size: 0.0 Peak width: 0.0 minutes Data storage: Full Stop time: No Limit The stop time was set to No Limit to allow extension of the run time until completion of D analysis of all cuts. Drying gas flow: 0.0 L/min Nebulizer: 35 psig Drying gas temperature: 00 C Sheath gas temperature: 300 C Sheath gas flow: 0.0 L/min Capillary voltage:,500 V Nozzle voltage: 300 V D-LC Mode Flow rate Sampling table Peak detection ASM D Gradient Heart-cutting 0.500 ml/min D-LC.00 minute time based with 0.08 minutes sampling time 4.00 minutes peak based with 0.5 minutes sampling time 6.50 minutes peak based with 0.5 minutes sampling time 8.00 minutes peak based with 0.5 minutes sampling time 8.50 minutes peak based with 0.45 minutes sampling time 0.00 minutes off Mode: slope Upslope: 3 mau/s Downslope: mau/s ASM and D gradient Method without the use of ASM ASM disabled 0.00 minutes 5 %B 3.00 minutes 60 %B D gradient stop time: 3.00 minutes D cycle time: 5 minutes ASM and D gradient Method with the use of ASM using an ASM factor of 3.0 ASM D Gradient ASM capillary: 5500-30 (0. 70 mm) ASM enabled (ASM factor: 3.0) Flush sample loop 3.0 times (0.74 minutes) 0.00 minutes 3 %B 0.74 minutes 3 %B 0.75 minutes 5 %B 3.75 minutes 60 %B D gradient stop time: 3.75 minutes D cycle time: 5.75 minutes ASM and D gradient Method with the use of ASM using an ASM factor of 5. ASM D Gradient ASM capillary: 5500-300 (0. 85 mm) ASM enabled (ASM factor: 5.) Flush sample loop 3.0 times (.3 min) 0.00 minutes 3 %B.3 minutes 3 %B.4 minutes 5 %B 4.4 minutes 60 %B D gradient stop time: 4.4 minutes D cycle time: 6.4 minutes 4

Results and Discussion The incompatibility between the D and D solvent systems is often referred to as one of the major challenges in D-LC method development. ASM provides a valve based approach to address this problem by diluting the D effluent with D mobile phase ahead of the D column. To enable ASM, a valve topology consisting of the D-LC Valve Active Solvent Modulation (G443A) and two MHC valves (G44-64000) is used. Figure shows the valve configuration. Figure explains the principle of active solvent modulation by showing the valve switching cycle. In position, a fraction from the D is sampled in Deck A (MHC valve A). Meanwhile, the flow from the D pump flows through Deck B (MHC valve B). Once the analysis of the fraction sampled in Deck A starts, the ASM valve switches to position. The flow coming from the D pump enters the ASM valve at port 5, and is split inside the valve between Deck A (port 8) and the ASM capillary (port 6). At port 0, the D flows through Deck A and the ASM capillary are reunited and led towards the D column. In this valve position, the fraction of D effluent that was sampled in Deck A is diluted with D solvent before it reaches the D column. Using weak D solvent, focusing of the analytes at the head of the D column is achieved. The ASM valve stays in position until the fraction of D effluent is entirely transferred to the D (ASM phase). Once the transfer of the fraction is finished, the ASM valve switches to position 3. Now the entire flow coming from the D pump flows through Deck A, and the ASM capillary is disconnected from the flow. The ASM valve stays in position 3 until the end of the D analysis of the transferred fraction. Meanwhile, fractions from the D effluent can be sampled on Deck B. Figure. Valve topology for ASM, countercurrent configuration. Deck A.. D-Pump 4 Deck B 3 5 6 7 8 Deck A 4. 3. D-Pump 4 Deck B 3 5 6 7 8 9 9 0 0 Waste Waste D-Pump D-Pump 4 Deck B 4 Deck B 3 3 5 5 6 7 6 7 8 8 Deck A Waste 0 9 Deck A Waste 0 9 Figure. Valve switching cycle for ASM, countercurrent configuration. 5

Once the analysis of a fraction of D effluent sampled in Deck B starts, the ASM valve switches to position 4 during the ASM phase to enable dilution of the D effluent with D solvent. After the ASM phase, the ASM valve switches back to position, and the ASM capillary is again disconnected from flow. The ASM factor describes the dilution of the sampled fraction of D effluent, which results from the split ratio between the deck and the ASM capillary. This split ratio depends on the backpressures generated at the ASM capillary and the flowpath through the deck. In the flowpath through the deck, the backpressure is mainly generated by the transfer capillaries between the ASM valve and the MHC valve. Different ASM capillaries are available to adjust the split ratio and the ASM factor (Table 3). If, for example, ASM capillary 5500 30 (0. 340 mm) is installed, it will generate the same backpressure as the transfer capillaries between the ASM valve and the MHC valve (two capillaries of 0. 70 mm). Therefore, the flow from the D pump is split with a ratio of : between the deck and the ASM capillary. This dilutes the sampled fraction of D effluent by a factor of approximately (ASM factor ). To use ASM, the ASM valve needs to be installed and configured in the D-LC configuration, as shown in Figure. The installed ASM capillary as well as transfer capillaries need to be defined in the D-LC configuration, as shown in Figure 3. In the D-LC method, the use of ASM is activated and the length of the ASM phase is defined by specifying how many sample loop volumes are flushed through the loop to the D in the valve position where dilution takes place (Figure 4). The resulting duration of the ASM phase is displayed. Flushing the sample loop three times is typically enough to achieve quantitative transfer and the recommended default. Table 3. Available ASM capillaries. ASM Capillary Length (mm) ID (mm) Volume (µl) ASM factor* Split ratio* (loop: ASM) 5500-300 85 0. 0.96 5 :4 5500-30 70 0..9 3 : 5500-30 340 0. 3.8 : 5500-303 680 0. 7.7.5 :0.5 * ASM factor and split ratio are based on transfer capillaries 5500-70 (0. 70 mm) and depend on solvent viscosity in the flowpaths through the ASM and transfer capillaries. Figure 3. Configuration of the ASM capillary in the D-LC configuration. Figure 4. Activation of ASM and method setup in the D-LC method. 6

In the D-LC method, D gradients that were initially programmed without the use of ASM need to be delayed by the duration of the ASM phase. The D gradient stop time and D cycle time need to be increased accordingly. For effective use of ASM, a solvent composition with low strength is chosen during the ASM phase. Figure 5 demonstrates the change from a D gradient initially programmed without the use of ASM (Figure 5A) to a D gradient with the use of ASM using an ASM phase of 0.4 minutes duration (Figure 5B). A %B 00 80 60 40 0 0 0 0.5.0 Time (min).5 B %B 00 80 60 40 0 0 0 0.5.0 Time (min).5.0 Figure 5. D gradient setup. A) D gradient initially programmed without the use of ASM. B) D gradient with the use of ASM using an ASM phase of 0.4 minutes duration. 7

RPLC-RPLC Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) Figure 6 shows the MHC D-LC analysis of PAHs using RPLC in both dimensions. For this analysis, an Agilent ZORBAX Eclipse Plus PAH column was chosen as the D column, and a ZORBAX Eclipse Plus C8 column was used in the D. The retention of the PAHs is higher on the ZORBAX Eclipse Plus PAH column compared to the ZORBAX Eclipse Plus C8 column. Generally, it is beneficial for an RPLC-RPLC analysis to place the more retentive column in the D to achieve focusing at the head of the D column,3. Here, the more retentive column was deliberately placed in the D to show the challenge of this column order, and demonstrate that ASM enables focusing at the head of the D column. ASM therefore improves D resolution and sensitivity for this challenging combination. As shown in Figure 6B, without the use of ASM, the D PAH peaks are distorted due to the lack of focusing at the D column head. This lack of focusing is because of the high percentage of organic solvent contained in the fractions of D effluent transferred to the D. Figures 6C and 6D demonstrate that ASM enables focusing at the D column head, resulting in symmetrical and narrow D peaks. A B Cut 3 Cut 8 Cut 3 C D 9 Figure 6. Multiple heart-cutting D-LC analyses of PAHs. A) D chromatogram. B) D Chromatograms from the analysis without the use of ASM. C) D Chromatograms from the analysis with the use of ASM using an ASM factor of.5. D) D Chromatograms from the analysis with the use of ASM using an ASM factor of.5 (green trace) and using an ASM factor of (blue trace). 8

In Figure 6C, ASM was used with an ASM factor of.5, which leads to symmetrical and narrow D peaks. Figure 6D compares the D separations obtained using ASM with an ASM factor of.5 (green trace) and an ASM factor of (blue trace). Due to the higher dilution of D effluent enabled using an ASM factor of, a further reduction in D peak width and increased peak height and sensitivity was obtained. In cut 3, a coelution that was already visible as a shoulder using an ASM factor of.5 was partially resolved using an ASM factor of. To demonstrate that focusing at the D column head depends on the dilution of D effluent before the D column and not solely on the D gradient used, the analysis was performed using the same D gradient with an initial hold at 5 %B ( D gradient used during the analysis with an ASM factor of ) with the use of ASM (Figure 7, green trace) and without the use of ASM (Figure 7, blue trace). The fact that symmetrical and narrow D peaks are only obtained with the use of ASM clearly demonstrates the necessity of ASM to achieve focusing at the D column head. Cut 3 Cut 8 Cut 3 Figure 7. D Chromatograms from the multiple heart-cutting D-LC analysis of PAHs using the same D gradient with the use of ASM (green trace) and without the use of ASM (blue trace). 9

HILIC-RPLC Analysis of Peptides Figure 8 shows the MHC D-LC analysis of peptides using HILIC in the D and RPLC in the D. In the D chromatogram (Figure 8A), coelution of peptides is already visible for the later-eluting peaks. In Figures 8B D, the D extracted ion chromatograms (EICs) from the detected peptides are shown. Here, the most abundant ion detected for each peptide was extracted (for example, for peptide 9, EIC,050 was extracted, which corresponds to the [M+H] + ion of mol. wt.,099). Figure 8B shows the analysis without the use of ASM. The peptides react differently to the high amount of organic solvent contained in the fractions of D effluent transferred to the D compared to the PAHs. The peptides show a partial breakthrough with the plug of D effluent that was transferred to the D column. The percentage of peptide retained on the D column compared to the percentage that shows breakthrough is different for the different peptides analyzed. To confirm that the unretained peaks observed in the EICs originate from partial breakthrough of the peptides, the mass spectra of the A B Cut 3 Peptide 9 Cut 6 Peptide 3 Cut 8 Peptide 5 Cut 6 Peptide 6 Cut 8 Peptide C Peptide 9 Peptide 3 Peptide 5 Peptide 6 Peptide D Peptide 9 Peptide 3 Peptide 5 Peptide 6 Peptide Figure 8. Multiple heart-cutting D-LC analyses of peptides: A) D Chromatogram. B) D EICs from the analysis without the use of ASM. C) D EICs from the analysis with the use of ASM using an ASM factor of 3. D) D EICs from the analysis with the use of ASM using an ASM factor of 5. 0

retained and unretained peaks were compared. The similarity of these mass spectra confirms the partial breakthrough. As an example, this is shown for cut 3 in Figure 9. Figures 8C and 8D demonstrate that ASM enables complete retention of the peptides transferred to the D, and avoids the partial breakthrough observed without the use of ASM. Because of the focusing at the D column head, symmetrical D peaks were obtained. In Figure 8C, ASM was used with an ASM factor of 3, which avoids breakthrough for certain peptides (for example, peptide 9 in cut 3). For other peptides (for example, peptide 3 in cut 6), an ASM factor of 3 did not provide sufficient dilution of the D effluent with weak D solvent to allow complete retention of the peptide. For these peptides, an ASM factor of 5 was necessary to completely avoid breakthrough, as shown in Figure 8D. To demonstrate that avoiding breakthrough of the peptides depends on the dilution of D effluent before the D column and not solely on the D gradient used, the analysis was performed using the same D gradient with an initial hold at 3 %B ( D gradient used during the analysis with an Cut 3 MS at 0.4 minutes Cut 3 MS at.4 minutes [M+3H] 3+ [M+3H] 3+ ASM factor of 5) with the use of ASM (Figure 0, green trace) and without the use of ASM (Figure 0, blue trace). Without the use of ASM, breakthrough of the peptides was observed, confirming the necessity of ASM to achieve retention of the peptides. [M+H] + [M+H] + Figure 9. Mass spectra of the unretained (top) and retained (bottom) peak observed in cut 3 of the multiple heart-cutting D-LC analysis of peptides without the use of ASM. Cut 3 Peptide 9 Cut 6 Peptide 3 Cut 8 Peptide 5 Cut 6 Peptide 6 Cut 8 Peptide Figure 0. D EICs from the multiple heart-cutting D-LC analysis of peptides using the same D gradient with the use of ASM (green trace) and without the use of ASM (blue trace).

Conclusion One major challenge in D-LC method development can be the incompatibility between the D and D solvent systems. For combinations of separation systems where the analytes show low retention on the D column in the D effluent, volume overload effects such as breakthrough or broad and distorted peaks in the D can be observed. Active solvent modulation provides a valve based approach to address this problem by diluting the D effluent with D mobile phase ahead of the D column, thereby enabling focusing at the D column head. For an RPLC-RPLC analysis of PAHs, broad and distorted D peaks were observed without the use of ASM. Using ASM with an ASM factor of enabled focusing at the D column head, leading to symmetrical and narrow D peaks. During an HILIC-RPLC analysis of peptides, partial breakthrough of the peptides was observed in the D without the use of ASM. Complete retention of the peptides was achieved using ASM with an ASM factor of 5. References. Stoll, D. R.; Carr, P. W. Two Dimensional Liquid Chromatography: A State of the Art Tutorial. Analytical Chemistry 07, 89, 59-53.. Stoll, D. R.; et al. Active Solvent Modulation: A Valve-Based Approach To Improve Separation Compatibility in Two-Dimensional Liquid Chromatography. Analytical Chemistry 07, 89, 960-967. 3. Li, D.; Jakob, C.; Schmitz, O. Practical considerations in comprehensive two-dimensional liquid chromatography systems (LCxLC) with reversed-phases in both dimensions. Analytical and Bioanalytical Chemistry 05, 407, 53-67. www.agilent.com/chem This information is subject to change without notice. Agilent Technologies, Inc. 07 Printed in the USA, December, 07 599-8785EN